Men diagnosed with advanced prostate cancer have a median survival of about 30 months, with many patients surviving as along as 5 to 10 years. This relatively slow progression of advanced disease distinguishes prostate cancer from other common malignancies and creates a situation in which men age in the context of premature and severe male hormone deprivation due to adjuvant therapies. This hormone deprivation may well hasten mental and physical deterioration and lower the quality of life in a number of spheres. Since testosterone can be converted to estrogen, certain physical and mental effects of testosterone could reflect its peripheral conversion (via aromatase) to estradiol. Conversely, some of the negative effects of testosterone deprivation by LHRH agonists or therapeutic castration could be due to lowered levels of estradiol. Moreover, clinical and animal studies suggest psychosocial and physical health benefits from estrogen in males. It's reduction in prostate cancer patients, therefore, could contribute to their morbidity. We propose a prospective, blinded clinical trial of low-dose estradiol to test our major hypothesis that chronic, low dose oral 17-beta estradiol therapy will preserve the overall quality of life and mental, emotional, and physical health status of men maintained on treatment-related androgen deprivation. We will enroll 150 cognitively intact (Mini-Mental Status Exam score >23) metastatic prostate patients into a double-blind, placebo controlled prospective study of low-dose estrogen (17-beta micronized estradiol 0.5 mg per day) for one year. We will measure various aspects of quality of life and physical, mental, and social functioning at 10 weeks (T2), 6 months (T3) and 12 months (T4) after study entry.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Miami Coral Gables
Coral Gables
United States
Zip Code
Jensen, Sally E; Pereira, Deidre B; Whitehead, Nicole et al. (2013) Cognitive-behavioral stress management and psychological well-being in HIV+ racial/ethnic minority women with human papillomavirus. Health Psychol 32:227-30
Cruess, Dean G; Benedict, Catherine; Lattie, Emily G et al. (2013) Millon Behavioral Medicine Diagnostic (MBMD) Predicts Health-Related Quality of Life (HrQoL) over time among men treated for localized prostate cancer. J Pers Assess 95:54-61
Traeger, Lara; Penedo, Frank J; Benedict, Catherine et al. (2013) Identifying how and for whom cognitive-behavioral stress management improves emotional well-being among recent prostate cancer survivors. Psychooncology 22:250-9
Lopez, Corina R; Antoni, Michael H; Pereira, Deirdre et al. (2013) Stress Management, Depression and Immune Status in Lower Income Racial/Ethnic Minority Women Co-infected with HIV and HPV. J Appl Biobehav Res 18:37-57
Myers, Nicholas D; Brincks, Ahnalee M; Ames, Allison J et al. (2012) Multilevel modeling in psychosomatic medicine research. Psychosom Med 74:925-36
Zhou, Eric S; Penedo, Frank J; Bustillo, Natalie E et al. (2010) Longitudinal effects of social support and adaptive coping on the emotional well-being of survivors of localized prostate cancer. J Support Oncol 8:196-201
Zhou, Eric S; Penedo, Frank J; Lewis, John E et al. (2010) Perceived stress mediates the effects of social support on health-related quality of life among men treated for localized prostate cancer. J Psychosom Res 69:587-90
Dodd, Stacy M; Pereira, Deidre B; Marion, Ilona et al. (2009) Depressive symptoms and cervical neoplasia in HIV+ low-income minority women with human papillomavirus infection. Int J Behav Med 16:181-8
Marion, Ilona; Antoni, Michael; Pereira, Deidre et al. (2009) Distress, sleep difficulty, and fatigue in women co-infected with HIV and HPV. Behav Sleep Med 7:180-93
Traeger, Lara; Penedo, Frank J; Gonzalez, Jeffrey S et al. (2009) Illness perceptions and emotional well-being in men treated for localized prostate cancer. J Psychosom Res 67:389-97

Showing the most recent 10 out of 42 publications